VECT-HORUS

VECT-HORUS has developed a breakthrough technology platform "VECTrans®" based on the design and development of ligands (peptides or antibody-based) that facilitate the targeted delivery of therapeutic or imaging agents into the brain and other organs. By conjugating pharmaceutical agents to its ligands, also called vectors, VECT-HORUS enables their transport across the Blood Brain Barrier, which significantly impedes brain delivery of most drugs. Proof of concept of the technology was demonstrated in animal models for different vectorized molecules. Based on its potential to target specific receptors, notably those that are found at high levels in some pathological tissues, VECT-HORUS is also targeting cancers, where there is a high unmet medical need and other organs including skeletal and cardiac muscle. VECT-HORUS has signed two major licensing agreements in 2023 and more than 10 R&D collaborations with world-class pharmaceutical companies, global specialists in their applications. These have already resulted in multiple licensing and option agreements.